Skip to content

Use of Erythromycin in Mustard-Induced Bronchiolitis

Low-Dose Long-Term Prescription of Erythromycin in Mustard-Induced Bronchiolitis Obliterans

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00367419
Enrollment
Unknown
Registered
2006-08-22
Start date
Unknown
Completion date
Unknown
Last updated
2008-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Obliterating Bronchiolitis, Bronchiolitis Obliterans

Brief summary

We looked for the effectiveness of low-dose long-term prescription of erythromycin in mustard-induced bronchiolitis obliterans

Interventions

DRUGErythromycin

Sponsors

Baqiyatallah Medical Sciences University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
MALE

Inclusion criteria

* Documented chemical exposure * Clinical, spirometric and radiological findings were compatible with BO on High Resolution Computed Tomography (HRCT) * Non-responsiveness to high dose bronchodilator therapy

Exclusion criteria

* Radiographic evidence of pneumonia, active tuberculosis, lung carcinoma, or an infection that necessitated the use of an antibiotic * History of cigarette smoking and occupational exposure to toxic agents of hypersensitivity to macrolides * History of treatment with a systemic antibiotic within 7 days before the start of the study * Any investigational medicine within 4 weeks of the study * History of antibiotic injection within 6 weeks before the study * Concomitant Theophylline or Carbamazepine, unless their serum concentrations were regularly monitored * Patients who were in the exacerbation phase of their respiratory complications * Need to use medications interact with macrolides such as Digoxin, Theophylline and Carbamazepine * Systemic antibiotics * Systemic Corticosteroids * Admission to the hospital * Abnormal kidney or liver function

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026